V-9302 is an inhibitor of amino acid transporter 2 (ASCT2).1 It inhibits glutamine uptake with IC50 values of 9 and 9.6 ?M for the rat and human transporters, respectively. V-9302 also inhibits glutamine uptake in HEK293 cells and reduces cell viability of a variety of cancer cell lines, including HCT116, HT-29, COLO 205, and RKO cells (EC50s = 8.9, 9.4, 14.5, and 8.3 ?M, respectively).2 It reduces glutamine uptake into tumor tissue and prevents tumor growth in HCT116 and HT-29 mouse xenograft models expressing K-RasG13D and BRAFV600E mutations, respectively, when administered at a dose of 75 mg/kg per day for 21 days.
1.Schulte, M.L., Khodadadi, A.B., Cuthbertson, M.L., et al.2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transportBioorg. Med. Chem. Lett.26(3)1044-1047(2016) 2.Schulte, M.L., Fu, A., Zhao, P., et al.Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical modelsNat. Med.24(2)194-202(2018)
















